Generation-2 ROS1/NTRK drug: Repotrectinib for lung cancer with 91% remission rate
- Painkillers and Contraceptives: Risky Combination for Women
- IAEA Shutdown Soon Due to Japan Nuclear Water and Australia Submarines?
- Baby Crying Elicits Oxytocin Release in Mothers
- mRNA Vaccine Targeting Bacteria to Prevent Lyme Disease from Tick Bites
- Aspartame: Memory & Learning Deficits and Transgenerational Effects
- Mysterious Circular RNA Linked to Alzheimer’s and Parkinson’s Diseases
Generation-2 ROS1/NTRK drug: Repotrectinib for lung cancer with 91% remission rate
- Nearly 300 People Food Poisoning in Japanese 130-Year Restaurant
- FDA’s First Potential TIL Therapy Review Delayed: How to Understand FDA’s “Resource Constraints”?
- A Chinese Doctor Accused of Accepting Bribes Totaling US$166 Million
- Nuclear contaminated water: Japanese government paid bribes and corrected the IAEA report
- Top 20 Companies of Instruments and Medical Equipment In The World
- The first DMD gene therapy SRP-9001 may cost 4 million US dollars
- How long can the patient live after heart stent surgery?
Generation-2 ROS1/NTRK drug: Repotrectinib for lung cancer with 91% remission rate.
As the cancer with the highest morbidity and mortality rate in the world, the progress and approval of new lung cancer drugs have shown a blowout state in the past two years.
Especially in the field of lung cancer, targeted therapy drugs targeting specific mutated genes (such as EGFR, ALK, ROS1, MET, RET, NTRK, KRAS targeted therapy) have further improved the survival hope of many lung cancer patients.
At the American Society of Clinical Oncology Annual Meeting (ASCO) held in June 2019, the data of Repotrectinib (TPX-0005), a new targeted drug that swept across the three targets of ALK/ROS1/NTRK, was amazing.
Repotrectinib is a new generation of oral multi-targeted drug developed by Turning Point Therapeutics in the United States. It has inhibitory effects on ALK, ROS1 and NTRK. It can overcome a variety of gene mutations that are resistant to other TKIs and kill ROS1. , NTRK and ALK positive solid tumors.
The FDA granted priority approval to repotrectinib, which is expected to be on the market by the end of 2023!
According to “Onclive”, on May 30, FDA granted Repotrectinib a priority review qualification for the treatment of ROS1-positive locally advanced or patients with metastatic non-small cell lung cancer.
This qualification is based on the results of the phase I/II TRIDENT-1 trial, and Ribotinib will be approved before November 27, 2023 if it goes well .
It is worth mentioning that if the progress goes well this time, this drug is expected to be approved for marketing in China and the United States in the second half of this year, which will also become the “pioneer” among the second-generation NTRK/ROS1 inhibitors.
Generation-2 ROS1/NTRK drug: Repotrectinib for lung cancer with 91% remission rate
(source:internet, reference only)
Disclaimer of medicaltrend.org
